The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.
Open accessAbstract
An enhanced appreciation of uptake mechanisms and intracellular trafficking of phosphorothioate modified oligodeoxynucleotides (P-ODN) might facilitate the use of these compounds for experimental and therapeutic purposes. We addressed these issues by identifying cell surface proteins with which P-ODN specifically interact, studying P-ODN internalization mechanisms, and by tracking internalized P-ODN through the cell using immunochemical and ultrastructural techniques. Chemical cross-linking studies with a biotin-labeled P-ODN (bP-ODN), revealed the existence of five major cell surface P-ODN binding protein groups ranging in size from approximately 20-143 kD. Binding to these proteins was competitively inhibited with unlabeled P-ODN, but not free biotin, suggesting specificity of the interactions. Additional experiments suggested that binding proteins likely exist as single chain structures, and that carbohydrate moieties may play a role in P-ODN binding. Uptake studies with 35S-labeled P-ODN revealed that endocytosis, mediated by a receptor-like mechanism, predominated at P-ODN concentrations < 1 microM, whereas fluid-phase endocytosis prevailed at higher concentrations. Cell fractionation and ultrastructural analysis demonstrated the presence of ODN in clathrin coated pits, and in vesicular structures consistent with endosomes and lysosomes. Labeled ODN were also found in significant amounts in the nucleus, while none was associated with ribosomes, or ribosomes associated with rough endoplasmic reticulum (ER). Since nuclear uptake was not blocked by wheat germ agglutinin or concanavalin A, a nucleoporin independent, perhaps diffusion driven, import process is suggested. These data imply that antisense DNA may exert their effect in the nucleus. They also suggest rational ways to design ODN which might increase their efficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C. A., & Cheng, Y.-C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,303
Characterization of oligonucleotide transport into living cells.
Loke, S. L., Stein, C. A., Zhang, X. H., Mori, K., Nakanishi, M., Subasinghe, C., Cohen, J. S., & Neckers, L. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3474 · Cited by 734
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo
Simons, M., Edelman, E. R., DeKeyser, J.-L., Langer, R., & Rosenberg, R. D. (1992) · Nature · doi:10.1038/359067a0 · Cited by 731
Current concepts in antisense drug design
Milligan, J. F., Matteucci, M. D., & Martin, J. C. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00066a001 · Cited by 566
Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?
Yakubov, L. A., Deeva, E. A., Zarytova, V. F., Ivanova, E. M., Ryte, A. S., Yurchenko, L. V., & Vlassov, V. V. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6454 · Cited by 509
Inhibition of in vitro nuclear transport by a lectin that binds to nuclear pores.
Finlay, D. R., Newmeyer, D. D., Price, T. M., & Forbes, D. J. (1987) · The Journal of cell biology · doi:10.1083/jcb.104.2.189 · Cited by 509
Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-kappa B
Kitajima, I., Shinohara, T., Bilakovics, J. M., Brown, D., Xu, X., & Nerenberg, M. I. (1993) · Science · doi:10.1126/science.8456277 · Cited by 278
Roghani, M., Mansukhani, A., Dell'Era, P., Bellosta, P., Basilico, C., Rifkin, D. B., & Moscatelli, D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41730-3 · Cited by 261
Bennett, R. M., Gabor, G. T., & Merritt, M. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112226 · Cited by 240
Cited by
CpG Motifs in Bacterial DNA and Their Immune Effects
Krieg, A. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064842 · Cited by 2,573
Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
Mishra, S., Webster, P., & Davis, M. E. (2004) · European Journal of Cell Biology · doi:10.1078/0171-9335-00363 · Cited by 730
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582
Metadata
- Authors
- Beltinger, C., Saragovi, H. U., Smith, R. M., LeSauteur, L., Shah, N., DeDionisio, L., Christensen, L., Raible, A., Jarett, L., & Gewirtz, A. M.
- Venue
- Journal of Clinical Investigation
- Published
- 1995-04-01
- Volume
- 95
- Issue
- 4
- Pages
- 1814-1823
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2065656306
- Cited by
- 312
- References
- 25
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. https://app.cochat.ai/papers/10.1172/jci117860
- The paper
- Beltinger, C., Saragovi, H. U., Smith, R. M., LeSauteur, L., Shah, N., DeDionisio, L., Christensen, L., Raible, A., Jarett, L., & Gewirtz, A. M. (1995). Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. Journal of Clinical Investigation. https://doi.org/10.1172/jci117860
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.